Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZON tezepelumab pediatric severe asthma study
2022-502984-39-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Tezepelumab with Matching placebo (2 arms). Primary endpoint: Annualized asthma exacerbation rate. Planned start Dec 2023; status: authorised.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on 2022-502984-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502984-39-00.